At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Bevacizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and Laboratory Biomarker Analysis for Malignant Ovarian Epithelial Tumor and 7 related conditions. Completed, enrolled 36 participants across 36 sites.
Detailed Summary
This phase II trial studies how well bevacizumab works in treating patients with sex cord-stromal tumors of the ovary that have come back. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Ovarian Epithelial Tumor, Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types, Ovarian Steroid Cell Tumor
CountriesUnited States
CollaboratorsNRG Oncology
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartSep 2008
Primary CompletionJan 2013
TodayJul 2026
First PostedSep 8, 2008
Enrollment StartSep 22, 2008
Primary CompletionJan 31, 2013
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 17.8 years ago
Interventions
Bevacizumabbiological
Given IV
Laboratory Biomarker Analysisother
Correlative studies